Literature DB >> 9217244

Summary of the II International Consensus Symposium on Combined Antiviral Therapy and implications for future therapies.

M D de Jong1, C A Boucher, D A Cooper, G J Galasso, B Gazzard, J M Lange, J S Montaner, D D Richman, H C Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9217244      PMCID： PMC7173273          DOI： 10.1016/s0166-3542(97)00020-x

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  129 in total

1.  Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus.

Authors:  R G Nador; E Cesarman; A Chadburn; D B Dawson; M Q Ansari; J Sald; D M Knowles
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

2.  The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission.

Authors:  D H Kedes; E Operskalski; M Busch; R Kohn; J Flood; D Ganem
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

3.  Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin.

Authors:  D Emanuel; I Cunningham; K Jules-Elysee; J A Brochstein; N A Kernan; J Laver; D Stover; D A White; A Fels; B Polsky
Journal:  Ann Intern Med       Date:  1988-11-15       Impact factor: 25.391

Review 4.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

5.  Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients.

Authors:  E T Lennette; D J Blackbourn; J A Levy
Journal:  Lancet       Date:  1996-09-28       Impact factor: 79.321

Review 6.  Treatment and prevention options for respiratory syncytial virus infections.

Authors:  M J Levin
Journal:  J Pediatr       Date:  1994-05       Impact factor: 4.406

7.  Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in ovo.

Authors:  M Hosoya; S Shigeta; T Ishii; H Suzuki; E De Clercq
Journal:  J Infect Dis       Date:  1993-09       Impact factor: 5.226

8.  Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial.

Authors:  W J Rodriguez; C B Hall; R Welliver; E A Simoes; M E Ryan; H Stutman; G Johnson; R Van Dyke; J R Groothuis; J Arrobio
Journal:  J Pediatr       Date:  1994-07       Impact factor: 4.406

9.  Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children.

Authors:  V G Hemming; W Rodriguez; H W Kim; C D Brandt; R H Parrott; B Burch; G A Prince; P A Baron; R J Fink; G Reaman
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

10.  Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone.

Authors:  R Schvarcz; Z B Yun; A Sönnerborg; O Weiland
Journal:  J Med Virol       Date:  1995-05       Impact factor: 2.327
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.